TLR7 and lung carcinoma: Furthermore, different types of CpG ODN like DV281 (Class C) and TLR7/8 agonists are being used in combination with immune checkpoint inhibitors like an anti-PD-1 antibody to induce immune cytokine and chemokine responses during lung cancer immunotherapy (Table 3) (40).